Skip to main content
Springer logoLink to Springer
. 2025 Aug 28;27(6):749–759. doi: 10.1007/s40272-025-00715-4

Long-Term Efficacy and Safety of Secukinumab in Children and Adolescents with Moderate-to-Severe Chronic Plaque Psoriasis: Four-Year Results of a Randomized, Phase III, Open-Label Trial

Kulli Kingo 1,✉, Philemon Papanastasiou 2, Stefan Beissert 3, Svetlana Lazareva 4, Asunción Vicente Villa 5, Jirina Bartonova 6, Rosalia Ballona 7, Amita Bansal 2, Ruvie Martin 8, Heng Fan 9, Charles O’Doherty 10, Shoba Ravichandran 8, Nina Magnolo 11
PMCID: PMC12534278  PMID: 40874954

Abstract

Background

The efficacy and safety of secukinumab up to week 52 in children and adolescents with moderate-to-severe chronic plaque psoriasis have been demonstrated previously (NCT03668613). Herein, we report the long-term efficacy, safety, and tolerability of secukinumab over a period of up to 208 weeks.

Methods

In this randomized open-label trial, patients (6 to < 18 years) were randomized 1:1 to receive low-dose (LD; N = 42) or high-dose (HD; N = 42) secukinumab stratified by weight (< 25 kg, 25 to < 50 kg, or ≥ 50 kg) and disease severity (moderate or severe). Patients weighing < 25 kg received 75 mg secukinumab (both LD and HD); 25 to < 50 kg received 75 mg (LD) or 150 mg (HD) secukinumab; and ≥ 50 kg received 150 mg (LD) or 300 mg (HD) secukinumab. The study assessed Psoriasis Area and Severity Index (PASI) 75/90/100 response, Investigator’s Global Assessment modified 2011 (IGA mod 2011) 0/1 response, Children’s Dermatology Life Quality (CDLQI) 0/1 response, and safety. The impact of secukinumab treatment on physical development was also assessed.

Results

Overall, 79.8% (67 of 84) enrolled patients completed 4 years of treatment (secukinumab LD [N = 31] and secukinumab HD [N = 36]). Both treatment groups showed sustained PASI and IGA mod 0/1 responses throughout the treatment period (at week 208, PASI 75/90/100 [secukinumab LD: 96.3%/88.9%/51.9%; secukinumab HD: 87.9%/81.8%/72.7%] and IGA mod 2011 0/1 [secukinumab LD: 85.2%; secukinumab HD: 84.8%]). Mean PASI score remained low in both treatment groups, from week 12 through week 208; at week 208, mean percentage change in PASI scores from baseline was − 95.7% (mean absolute score: 18.46 [baseline]; 0.76 [week 208]) with secukinumab LD and − 94.5% (mean absolute score: 19.25 [baseline]; 1.07 [week 208]) with secukinumab HD. CDLQI 0/1 response remained high in both treatment groups from week 12 through week 208 (secukinumab LD: 75.0%; secukinumab HD: 88.2%). Safety profile of secukinumab with long-term (~313.9 patient-years) treatment was favorable and in line with the known safety profile reported previously for 52-week treatment. No dose-dependent safety observations were noted. There were no deaths recorded throughout the entire duration of the treatment. Nonfatal serious adverse events (SAEs) were reported in four (9.5%) patients in the LD group (coronavirus disease 2019 [COVID-19], Crohn’s disease, infectious mononucleosis, intentional self-injury, tibia fracture) and two (4.8%) patients in the HD group (appendicitis, tonsillitis). The incidence of treatment-emergent adverse events was similar in both secukinumab dose groups (LD [78.6%] and HD [83.3%]). No impact on the growth and development, or sexual maturation of pediatric patients, was noted with long-term treatment.

Conclusions

Secukinumab demonstrated sustained long-term efficacy and improved quality of life through week 208 in pediatric patients with moderate-to-severe chronic plaque psoriasis. The treatment was well tolerated, and safety data were consistent with the known favorable safety profile of secukinumab.

Clinical trial registration no. NCT03668613

Supplementary Information

The online version contains supplementary material available at 10.1007/s40272-025-00715-4.

Key Points

Both low-dose (LD) and high-dose (HD) secukinumab treatment groups showed sustained long-term efficacy and improved health-related quality of life in children and adolescents with moderate-to-severe chronic plaque psoriasis over a period of up to 208 weeks, except for PASI 100 and CDLQI response rates, which were numerically higher in the HD group.
Secukinumab showed favorable safety with long-term (up to 208 weeks) use with no dose-dependent observations. Secukinumab was well tolerated at low and high doses.
No impact on the growth and development, or sexual maturation of pediatric patients, was noted with long-term secukinumab treatment.

Introduction

Psoriasis is a chronic relapsing inflammatory skin disease that affects approximately 1% of children, with its onset being most common during adolescence [1]. Pediatric plaque psoriasis typically manifests with patterns similar to those observed in adults. Lesions are commonly found on the scalp, post-auricular region, elbows, and knees. However, these lesions are usually smaller, thinner, and less scaly in children than in adults. Pediatric psoriasis also tends to involve the face and flexural regions more frequently than adult psoriasis, and psoriatic lesions in the diaper area are commonly seen during infancy [2–4]. Pediatric psoriasis is often linked to significant comorbidities such as hypertension, high cholesterol, obesity, and diabetes mellitus [5, 6], all of which have a profound impact on quality of life. The psychological impact of psoriasis can be particularly traumatic to both children and adolescents [7]. The pediatric population has access to a smaller range of approved treatments, including both topical and systemic approaches, when compared with those available for adults [7–10].

Secukinumab, a fully human monoclonal antibody that selectively neutralizes interleukin (IL)-17A, was approved for moderate-to-severe plaque psoriasis in children and adolescents in the European Union (2020) [11] and the USA (2021) [12] and most countries since then [13]. Currently approved biologics for pediatric psoriasis, other than secukinumab, include adalimumab, etanercept, ixekizumab, and ustekinumab as approved by the European Medicines Agency (EMA), and ixekizumab, etanercept, and ustekinumab, as approved by the US Food and Drug Administration (FDA) [12, 13]. However, the treatment of pediatric psoriasis is challenging because of the lack of comprehensive data regarding the long-term safety and effectiveness of approved therapies. The efficacy and safety of secukinumab up to week 52 have been reported previously in a pivotal phase III study in children and adolescents with moderate-to-severe chronic plaque psoriasis (NCT03668613) [14]. Herein, we report the long-term efficacy, safety, and tolerability of secukinumab over a period of up to 208 weeks.

Methods

Study Design

This is the final analysis of a pivotal phase III open-label, parallel group, two-arm, multicenter, randomized study in pediatric patients aged 6 years to < 18 years with moderate-to-severe chronic plaque psoriasis (NCT03668613). The study design has been published previously [15]. Patients were randomized (1:1) to receive subcutaneous low-dose (LD) secukinumab (75 or 150 mg) or high-dose (HD) secukinumab (75, 150, or 300 mg). At randomization, patients were stratified by weight (< 25 kg, 25 to < 50 kg, and ≥ 50 kg) and disease severity (moderate and severe). The patients received secukinumab doses on the basis of their body weight. Patients weighing < 25 kg received 75 mg (both LD and HD secukinumab groups). Patients weighing 25 to < 50 kg received 75 mg (LD group) or 150 mg (HD group) secukinumab. Patients weighing ≥ 50 kg received 150 mg (LD group) or 300 mg (HD group) secukinumab. If the patient moved into a higher or lower weight group at two consecutive visits during the treatment period, then the patient was dosed according to the new (higher or lower, respectively) weight group. The study included three periods: screening (up to 4 weeks), treatment (208 weeks), and post-treatment follow-up (16 weeks). A historical placebo control was used as the comparator in the Bayesian analysis (meta-analytic-prior approach) performed on primary and key secondary efficacy endpoints. This was in line with the guidance from and discussions with health authorities, including the US FDA and EMA. Details of the historical placebo have been published previously [15]. The study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines and in compliance with all national, federal, local, or regional requirements. The institutional review board/ethics committee of each participating center approved the study protocol.

Study Population

Patients (6 to < 18 years old) with a diagnosis of moderate-to-severe chronic plaque psoriasis (Psoriasis Area and Severity Index [PASI] score of ≥ 12, Investigator’s Global Assessment modified 2011 [IGA mod 2011] score of ≥ 3, and body surface area involvement of ≥ 10%), and a history of plaque psoriasis for ≥ 3 months were included in the study. Details of the patient population have been published previously [15].

Assessments

The long-term efficacy of secukinumab in terms of PASI (75/90/100) responses and IGA mod 2011 (0/1) response over time up to the end of treatment (EOT) were evaluated. Changes in the Children’s Dermatology Life Quality Index (CDLQI) response (0/1) and the CDLQI total score over time up to EOT were assessed. Relapse and rebound assessments were conducted after the last study treatment. Relapse was defined as a > 50% reduction in maximum PASI improvement from baseline (after the last treatment administration); rebound was defined as a PASI increase to > 125% of baseline PASI, or occurrence of rebound psoriasis (preferred term [PT]) or pustular psoriasis (PT), erythrodermic psoriasis (PT) or more inflammatory psoriasis (verbatim term) occurring within 8 weeks after the last dose of the study treatment that was administered and within 12 weeks after the last dose defined for rebound-like events. Long-term clinical safety and tolerability of secukinumab up to the end of the study were assessed. Adverse events (AEs) were grouped by primary system organ class (SOC) and by preferred term (PT) according to the Medical Dictionary for Regulatory Activities (MedDRA) version 26.0. AEs and serious AEs (SAEs) were summarized for each treatment group by presenting the number and percentage of patients with any AE, with an AE in each primary SOC, and with individual AEs (PT). The impact of secukinumab treatment on sexual maturation was assessed using Tanner staging (1 [prepubertal] to 5 [full sexual maturation]). Development of immunogenicity against secukinumab was assessed by the detection of antidrug antibodies (ADAs).

Statistical Analyses

Efficacy analyses were based on the full analysis set (all patients from the randomized set to whom study treatment was assigned). Analyses of long-term data beyond week 52 were based on observed data for all efficacy endpoints. Summaries of PASI 75/90/100 and IGA mod 2011 0/1 responses over time are presented descriptively. Summary statistics are provided for absolute PASI scores, as well as percentage change from baseline by visit and treatment group for PASI score, using observed data. Summary statistics are provided for the number of patients achieving a CDLQI response of 0 or 1, and for the CDLQI total score for relapse and rebound, summary statistics are presented after the last treatment administration on the basis of evaluable patients. All safety analyses were based on the safety analysis set (all patients who took at least one dose of the study drug during the treatment period). The detailed methodology for the statistical analysis for safety has been described previously [15].

Results

Patient Disposition

Of the 84 randomized patients (secukinumab LD [N = 42] and secukinumab HD [N = 42]), 79.8% (67 of 84) completed the treatment (secukinumab LD [N = 31] and secukinumab HD [N = 36]), whereas 20.2% (17 of 84) discontinued it (secukinumab LD [N = 11] and secukinumab HD [N = 6]). The most common reason for discontinuation during the entire study treatment was lack of efficacy (5 [11.9%]) and patient decision (2 [4.8%]) in the secukinumab LD group and AE (2 [4.8%]) and pregnancy (2 [4.8%]) in the secukinumab HD group (Fig. 1).

Fig. 1.

Fig. 1

Patient disposition

Demographics and Baseline Disease Characteristics

The demographics and baseline disease characteristics were comparable between the secukinumab LD and HD groups and have been reported previously [14]. The mean age of the patients was 12.6 years and was similar in both treatment groups. Most patients (51 of 84 patients; 60.7%) belonged to the age group of 12 to < 18 years (Supplementary Table 1).

Efficacy

PASI 75/90/100 and IGA 0/1 responses remained high in both treatment groups from week 12 through EOT (week 208). At week 208, secukinumab-treated patients showed sustained PASI 75/90/100 (secukinumab LD: 96.3%/88.9%/51.9%; secukinumab HD: 87.9%/81.8%/72.7%) and IGA mod 2011 0/1 (secukinumab LD: 85.2%; secukinumab HD: 84.8%) responses (Fig. 2a–d). PASI 75 and IGA mod 2011 0/1 response rates increased continuously from baseline, reaching maximum values between weeks 24 and 32; thereafter, the PASI 75 and IGA mod 2011 0/1 response rates remained similar between the LD and HD groups at almost all timepoints until week 208 (Fig. 2a and b). In most assessments, PASI 90 responses were slightly higher in the HD group after week 24 until week 156 but lower after week 156 and until week 208 (Fig. 2c). After week 24 through week 208, PASI 100 response was numerically greater in the HD group (Fig. 2d).

Fig. 2.

Fig. 2

Efficacy response rates up to week 208 using observed cases a IGA mod 2011 0/1; b PASI 75; c PASI 90; d PASI 100. HD high dose, IGA mod 2011 Investigator’s Global Assessment modified 2011, LD low dose, PASI Psoriasis Area and Severity Index

At week 12, mean percentage change in PASI score from baseline was − 92.6% (mean absolute score: 1.42) in the LD group and − 93.9% (mean absolute score: 1.19) in the HD group. The mean PASI score remained low in both treatment groups, from week 12 through week 208, and at week 208, mean percentage change in PASI scores from baseline was − 95.7% (mean absolute score: 0.76) with secukinumab LD and − 94.5% (mean absolute score: 1.07) with secukinumab HD (Fig. 3 and Supplementary Fig. 1).

Fig. 3.

Fig. 3

Change in PASI scores from baseline by visit (observed cases) over time up to week 208. HD high dose, LD low dose, PASI Psoriasis Area and Severity Index

Health-Related Quality of Life

CDLQI 0/1 response remained high in both treatment groups from week 12 through week 208 (secukinumab LD: 75.0%; secukinumab HD: 88.2%; Fig. 4). CDLQI 0/1 response rates were higher in the HD group after week 180 to 208 compared with the LD group. Mean percentage change in CDLQI total score was overall comparable between the two treatment groups up to week 52. At week 52, mean absolute change in CDLQI total score was − 9.2 (− 84.9% from baseline) and − 12.8 (− 89.6% from baseline) in the LD and HD groups, respectively, and between weeks 52 and 208, the mean absolute and percent change in CDLQI total score was generally similar in both groups. At week 208, the mean absolute percent change from baseline in CDLQI total score was − 9.3 (− 92.3%) and − 11.2 (− 92.7%) in the LD and HD groups, respectively (Supplementary Fig. 2).

Fig. 4.

Fig. 4

CDLQI 0/1 response up to week 208 in LOCF analysis. N represents the number of patients in each treatment group included in the full analysis set. CDLQI Children’s Dermatology Life Quality Index, HD high dose, LD low dose, LOCF last observation carried forward

Relapse and Rebound

The proportion of patients experiencing at least one relapse during the entire treatment period was higher in the secukinumab LD group. After the last study treatment, 8 of 41 (19.5%) patients in the LD group and 4 of 41 (9.8%) patients in the HD group had relapse. Of the eight patients who experienced relapse in the LD group, three had discontinued the treatment owing to lack of efficacy. The remaining five patients had their relapse between 120 and 157 days after their last dose. Similarly, the four patients in the HD group had their first relapse event 98–140 days after their last dose. No patient experienced rebound or rebound-like events up to 8 and 12 weeks, respectively, after the last study treatment.

Safety

The median duration of exposure during the entire treatment period was 1513.0 days in the secukinumab LD group and 1512.5 days in the secukinumab HD group. Cumulative exposure across the secukinumab treatment groups was similar, totaling 313.9 patient-years (PYs) in the “any secukinumab” group. Overall, 81.0% (68 of 84) of patients had at least one AE. The incidence of AEs was comparable between the secukinumab LD (33 of 42 [78.6%]) and HD (35 of 42 [83.3%]) groups (Table 1). No deaths were reported during the entire treatment period. AEs leading to treatment discontinuation for the entire treatment period were also infrequent and comparable in both treatment groups (one patient in the LD group and two patients in the HD group). Nonfatal SAEs during the entire treatment period were reported in four (9.5%) patients in the LD group and two (4.8%) patients in the HD group. Consistent with the week 52 results, the most frequently affected SOCs in the “any secukinumab” group were infections and infestations (55 of 84, 65.5%), gastrointestinal disorders (19 of 84, 22.6%), and skin and subcutaneous tissue disorders (19 of 84, 22.6%).

Table 1.

Overall safety profile—entire treatment period (safety analysis set)

Secukinumab LD
N = 42
Secukinumab HD
N = 42
Any secukinumab
N = 84
Exposure (PYs) 156.1 157.8 313.9
Any primary SOC: n, IR (95% CI) 33, 62.8 (43.2–88.2) 35, 74.5 (51.9–103.6) 68, 68.3 (53.0–86.6)
Death 0 0 0
Nonfatal SAEs, n (%) 4 (9.5) 2 (4.8) 6 (7.1)
Discontinuation due to any AE, n (%) 1 (2.4) 2 (4.8) 3 (3.6)
Most frequent AEs (by SOC): n, IR (95% CI)
 Infections and infestations 27, 35.0 (23.1–50.9) 28, 41.9 (27.8–60.5) 55, 38.2 (28.8–49.7)
 Gastrointestinal disorders 9, 6.7 (3.1–12.8) 10, 7.4 (3.6–13.7) 19, 7.1 (4.3–11.1)
 Skin and subcutaneous tissue disorders 12, 9.5 (4.9–16.6) 7, 4.8 (1.9–9.8) 19, 6.9 (4.2–10.8)
Most frequent AEs (by PT): n, IR (95% CI)
 COVID-19 12, 8.9 (4.6–15.5) 9, 6.2 (2.8–11.8) 21, 7.5 (4.6–11.5)
 Nasopharyngitis 13, 10.7 (5.7–18.2) 7, 5.2 (2.1–10.7) 20, 7.8 (4.8–12.1)
 Acne 7, 5.0 (2.0–10.2) 2, 1.3 (0.2–4.7) 9, 3.1 (1.4–5.8)
EAIRs for safety topics of interest: n, IR (95% CI)
 Infections and infestations (SOC) 27, 35.0 (23.1–50.9) 29a, 45.4 (30.4–65.3) 56, 39.7 (30.0–51.6)
 Hypersensitivity (SMQ) (narrow) 7, 4.9 (2.0–10.2) 1, 0.6 (0.0–3.6) 8, 2.7 (1.2–5.3)
 Neutropenia (NMQ) (narrow) 4, 2.8 (0.8–7.2) 2, 1.3 (0.2–4.7) 6, 2.0 (0.7–4.4)
 Candida infection (HLT) 2, 1.3 (0.2–4.7) 0, 0.0 (0.0–2.3) 2, 0.6 (0.1–2.3)
 Vaccination-related complications (HLT) 1, 0.6 (0.0–3.6) 1, 0.6 (0.0–3.5) 2, 0.6 (0.1–2.3)
 IBD (NMQ) (narrow) 1, 0.6 (0.0–3.6) 1, 0.6 (0.0–3.5) 2, 0.6 (0.1–2.3)
 Suicide/self-injury (SMQ) 1, 0.6 (0.0–3.6) 0, 0.0 (0.0–2.3) 1, 0.3 (0.0–1.8)

MedDRA version 26.0 was used for reporting.

AE adverse event, CI confidence interval, COVID coronavirus disease, EAIR exposure-adjusted incidence rate, HD high dose, HLT high-level term, IBD inflammatory bowel disease, LD low dose, N total number of patients, n number of patients, NMQ Novartis-customized MedDRA Query, PT preferred term, PY patient-year, SAE serious adverse event, SMQ standardized MedDRA Query, SOC system organ class

aThe term “lip wart” (PT: oral papilloma) was included in the SOC infections and infestations for this specific table. However, it was categorized as SOC neoplasms benign for all other general adverse event tables. This is why there is an additional patient listed under the HD group

The exposure-adjusted incidence rates (EAIR) of the most commonly reported SOCs were similar in the secukinumab LD and HD groups under infections and infestations (secukinumab LD, 35.0/100 PYs; secukinumab HD, 41.9/100 PYs). The EAIR of AEs under the SOC skin and subcutaneous tissue disorders was numerically higher in the secukinumab LD group (9.5/100 PYs) than in the HD group (4.8/100 PYs).

The most commonly reported AEs by PT were coronavirus disease 2019 (COVID-19); (secukinumab LD [12 of 42 {28.9%} and EAIR 8.9/100 PYs] and HD [9 of 42 {21.4%} and EAIR 6.2/100 PYs]), nasopharyngitis (secukinumab LD [13 of 42 {31.0%} and EAIR 10.7/100 PYs] and HD [7 of 42 {16.7%} and EAIR 5.2/100 PYs]), and acne (secukinumab LD [7 of 42 {16.7%} and EAIR 5.0/100 PY] and HD [2 of 42 {4.8%} and EAIR 1.3/100 PY]).

The most frequently reported AEs were under the safety topic of infections and infestations (EAIRs: “any secukinumab” LD, 35.0/100 PYs; “any secukinumab” HD, 45.4/100 PYs). Candida infections (high-level term [HLT]) were reported in two patients in the LD group (EAIR: 1.3/100 PYs [skin candida, 1; esophageal candidiasis, 1]) and none in the HD group. The proportion of patients with AEs in the safety topic of hypersensitivity (standardized MedDRA Query [SMQ], narrow) in the “any secukinumab” LD group was 16.7% (n = 7; EAIR: 4.9/100 PYs) and that in the “any secukinumab” HD group was 2.4% (n = 1; EAIR: 0.6/100 PYs). The higher incidence of hypersensitivity in the LD group (SMQ, narrow) was mainly driven by PTs of angioedema, contact dermatitis, drug hypersensitivity, eczema, erythema nodosum, hand dermatitis, and penile dermatitis. Neutropenia and leukopenia PTs qualified under neutropenia (Novartis-customized MedDRA Query [NMQ], narrow, NMQ corresponds to groupings defined by MedDRA and additional custom groupings created by Novartis) and were reported in six patients (7.1%; 4 [EAIR, 2.8/100 PYs] from the LD group and 2 [EAIR, 1.3/100 PYs] from the HD group). Inflammatory bowel disease (IBD) (NMQ) occurred in one patient (EAIR, 0.6/100 PYs) each in the secukinumab LD and HD groups. Two patients discontinued treatment due to AE: one patient (LD group) owing to moderate SAE of Crohn’s disease and one patient (HD group) owing to a mild AE of hemorrhagic diarrhea (not diagnosed as IBD) both events were resolved with concomitant treatment (Crohn’s disease SAE was resolved with sequelae). Suicide/self-injury (SMQ) was reported in one patient in the secukinumab LD group (EAIR: 0.6/100 PYs). Details of the patient have been published previously [13]. Two pregnancies were reported in the HD group, which led to discontinuation of the study drug as required by the protocol. Both women gave birth to healthy babies.

Tanner Staging of Pubertal Development

Most patients at baseline were pubertal or postpubertal (Tanner stage score of ≥ 2). Tanner staging scores increased over time, and the patients consistently moved toward higher Tanner stage scores from baseline through the study course. At baseline, Tanner stage 4 or 5 was observed in 31.8% of male and 50.0% of female patients in the “any secukinumab” LD group, and in 52.9% of male and 60.0% of female patients in the “any secukinumab” HD group. By week 104, the proportion of patients with Tanner stage 4 or 5 increased to 57.1% in males and 66.7% in females in the “any secukinumab” LD group, and to 76.5% in males and 76.2% in females in the HD group. At week 208, most of the evaluable male and female patients in the secukinumab LD group (male, 66.7%; female, 75.0% versus male, 70.6%; female, 71.4% in the secukinumab HD group) reached Tanner stage 5 (full sexual maturation). In addition, no adverse events associated with retardation of sexual maturation were reported. These data indicate that both secukinumab LD and HD did not have any effect on the sexual maturation of the patients treated in the study (Supplementary Fig. 3).

Immunogenicity

ADA development with secukinumab treatment for 208 weeks was low; 7 patients (3 in the LD and 4 in the HD group; 7 of 84, 8.3%) presented with positive treatment-emergent ADAs, with 6 having positive ADAs only during treatment-free follow-up. None of these patients developed neutralizing antibodies.

Discussion

Currently available biologics have demonstrated efficacy in treating pediatric psoriasis. Particularly, inhibitors of IL-12/23 and agents targeting IL-17A have shown the potential for greater efficacy than tumor necrosis factor-α inhibitors [16, 17]. Studies that assess the long-term efficacy and safety of these drugs in the pediatric population are essential for a comprehensive understanding of treatment effect, particularly for chronic immune-mediated inflammatory conditions such as plaque psoriasis. The long-term results from this study add on to those previously published at week 24 and week 52 and further confirm the benefits of secukinumab for the treatment of moderate-to-severe chronic plaque psoriasis in the pediatric population [14, 15]. Long-term data showed a sustained high efficacy. Similar results have been reported in pediatric patients with severe chronic plaque psoriasis, where secukinumab demonstrated sustained long-term efficacy (up to 2 years) [18]. High-efficacy response rates were observed in both dose groups and were sustained through EOT. PASI 75/90/100 responses at EOT in the current study were > 87%/ > 81%/ > 51% in both dose groups. In the long-term extension of the phase III adult psoriasis pivotal studies, ERASURE and FIXTURE, PASI 75/90/100 responses were reported to be > 80%/ > 62%/ > 30%, respectively, at year 5 with secukinumab 300 mg [19]. The results of the current pediatric study were consistent with those from the 5-year SCULPTURE extension study in adults, where the PASI 75/90/100 responses were reported to be 88.5%/66.4%/41%, respectively, at year 5 with secukinumab 300 mg [20].

Similar to the findings from the secukinumab severe pediatric psoriasis study [18] and to the moderate-to-severe adult psoriasis studies [19, 21, 22], both secukinumab LD and HD groups showed sustained improvement in CDLQI scores throughout 208 weeks of treatment, indicating improvement in the quality of life of pediatric patients. None of the patients experienced rebound or rebound-like events after the last treatment in the study. However, a higher proportion of patients in the LD group experienced relapse events than those in the HD group.

The long-term safety results corresponding to 313.9 PYs treatment exposure are consistent with those obtained at week 24 and week 52 in this study [14, 15]. The results were also consistent with the known safety profile for secukinumab in adults [19, 23] and pediatric patients with moderate-to-severe and severe plaque psoriasis [18]. No new safety signals were identified in this study, and no dose-dependent observations were noted. During the entire treatment period, only six patients reported neutropenia, which resolved without therapy. All the neutropenia events were mild to moderate in severity, and except for one, all were considered to be related to the study drug by the investigator.

This 4-year analysis is one of the longest reported randomized clinical trial of a biologic performed in pediatric patients with moderate-to-severe plaque psoriasis. The long treatment with secukinumab had no effect on the physical growth and development and on the sexual maturation of children and adolescents. The long-term findings of this study, which showed sustained efficacy and the favorable safety profile of secukinumab for over 4 years, provide valuable insights in treating moderate-to-severe chronic plaque psoriasis in pediatric patients. The limitations of the study include the open-label design without a direct control arm in the trial and the small sample size. In addition, the study population was predominantly white (> 90%), which may not reflect the racial distribution of individuals affected by the disease in terms of skin type in the general population. It is important to note that regulatory guidance from health authorities such as the FDA and EMA (PDCO) recommends minimizing placebo exposure and overall clinical trial burden in pediatric populations (EMA 2012) [24]. This guidance supports the use of an extrapolation approach, thereby justifying the absence of a direct control arm in this study.

Conclusions

Both low and high doses of secukinumab demonstrated sustained efficacy and improved health-related quality of life through the entire treatment period (up to EOT on week 208) in pediatric patients with moderate-to-severe plaque psoriasis. No new safety signals were identified. Secukinumab was well tolerated at both doses. Growth and development data did not show any notable adverse effects with secukinumab treatment in the pediatric population.

Supplementary Information

Below is the link to the electronic supplementary material.

Acknowledgements

The authors thank Rajib Kishore Hazam and Nivedita Jangale, (Novartis Healthcare Pvt. Ltd, Hyderabad, India) for providing editorial and medical writing support, which was funded by Novartis Pharma AG, Basel, Switzerland, in accordance with the Good Publication Practice (GPP 2022) guidelines (https://www.ismpp.org/gpp-2022).

Declarations

Funding

This study was funded by Novartis Pharma AG, Basel, Switzerland.

Conflicts of Interest

Kulli Kingo has received fees for serving as an investigator in studies sponsored by AbbVie, Celgene, Galderma, Merck, Mitsubishi Tanabe Pharma, Novartis, Regeneron Pharmaceuticals, and Sandoz. Stefan Beissert has been on the advisory board of AbbVie Deutschland GmbH & Co. KG, Actelion Pharmaceuticals Deutschland GmbH, Amgen GmbH, Celgene GmbH, Galderma Laboratorium GmbH, Janssen-Cilag GmbH, LEO Pharma GmbH, Lilly Deutschland GmbH, Novartis Pharma GmbH, MSD SHARP & DOHME GmbH, Menlo Therapeutics, Sanofi-Aventis Deutschland GmbH, Pfizer Pharma GmbH, and UCB Pharma GmbH and received speaker honorarium from Novartis Pharma GmbH, AbbVie Deutschland GmbH & Co. KG, MSD SHARP & DOHME GMBH, Pfizer Pharma GmbH, Janssen-Cilag GmbH, Galderma Laboratorium GmbH, Celgene GmbH, La Roche-Posay Laboratoire Pharmaceutique, Actelion Pharmaceuticals Deutschland GmbH, GlaxoSmithKline GmbH & Co. KG, Bristol Myers Squibb GmbH & Co. KGaA, Sanofi-Aventis Deutschland GmbH, Almirall Hermal GmbH, and Sandoz/Hexal AG. Svetlana Lazareva and Jirina Bartonova declare no conflicts of interest. Asunción Vicente Villa has been an investigator in studies, advisor, speaker, and/or consultant for AbbVie, Almirall, Amgen, Amryt, Boehringer Ingelheim, Bristol Myers Squibb, Ferrer, Galderma, Jansen, LEO Pharma, Lilly, Novartis, Pierre Fabre, Pfizer, and Sanofi-Genzyme. Rosalia Ballona has received fees for serving as an investigator in this study sponsored by Novartis. Nina Magnolo has been an advisor, speaker, and/or consultant for AbbVie, Almirall, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Janssen, La Roche-Posay, LEO Pharma, Lilly, Novartis, Pfizer, Sanofi, Dr. Wolff, Sanofi, and UCB Pharma. Amita Bansal, Ruvie Martin, Heng Fan, Charles O’Doherty, and Philemon Papanastasiou are employees and shareholders of Novartis. Shoba Ravichandran was a full-time employee at the time the research was conducted and is a current stockholder of Novartis.

Data Availability

The datasets generated and/or analyzed during the current study are not publicly available. Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. These requests are reviewed and approved on the basis of scientific merit. All data provided are anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. The data may be requested from the corresponding author of the manuscript.

Ethics Approval

The study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines and in compliance with all national, federal, local, or regional requirements. The institutional review board/ethics committee of each participating center approved the study protocol.

Consent

A parent or legal guardian provided written informed consent, and the patient provided written assent, at screening before any assessment was performed. If patients reached age of consent (as per local law) during the study, they needed to also sign the corresponding study informed consent(s).

Consent for Publication

Written informed consent was obtained from each patient or legal representative of the patient for anonymized patient information to be published.

Author Contributions

All authors were involved in the drafting and critical review of the manuscript and approved the final version for submission. K.K., S.B., S.L., A.V.V., J.B., R.B., and N.M. contributed to the design of the study and were involved in the acquisition of clinical data and participated as principal investigators in the clinical study from which data are reported in the manuscript. P.P., A.B., R.M., H.F., C.O.D., and S.R. were involved in the conception, design, and clinical conduct of the trial. R.M. and H.F. were involved in the analysis of the data in the manuscript. All authors were involved in the interpretation of data in the manuscript. All authors agreed to be accountable for all aspects of the work and attest to the accuracy and integrity of the work.

References

  • 1.Menter A, Cordoro KM, Davis DMR, Kroshinsky D, Paller AS, Armstrong AW, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. J Am Acad Dermatol. 2020;82(1):161–201. [DOI] [PubMed] [Google Scholar]
  • 2.Thomas J, Parimalam K. Treating pediatric plaque psoriasis: challenges and solutions. Pediatr Health Med Ther. 2016;7:25–38. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Pinson R, Sotoodian B, Fiorillo L. Psoriasis in children. Psoriasis (Auckl). 2016;6:121–9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Katakam BK, Munisamy M, Rao TN, Chiramel MJ, Panda M, Gupta S, et al. Recommendations for management of childhood psoriasis. Indian Dermatol Online J. 2021;12(Suppl 1):S71-s85. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Osier E, Wang AS, Tollefson MM, Cordoro KM, Daniels SR, Eichenfield A, et al. Pediatric psoriasis comorbidity screening guidelines. JAMA Dermatol. 2017;153(7):698–704. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Kang BY, O’Haver J, Andrews ID. Pediatric psoriasis comorbidities: screening recommendations for the primary care provider. J Pediatr Health Care. 2021;35(3):337–50. [DOI] [PubMed] [Google Scholar]
  • 7.Bronckers IM, Paller AS, van Geel MJ, van de Kerkhof PC, Seyger MM. Psoriasis in children and adolescents: diagnosis, management and comorbidities. Paediatr Drugs. 2015;17(5):373–84. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Bronckers I, Paller AS, West DP, Lara-Corrales I, Tollefson MM, Tom WL, et al. A comparison of psoriasis severity in pediatric patients treated with methotrexate vs biologic agents. JAMA Dermatol. 2020;156(4):384–92. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Goenaga-Vázquez Y, Lauck KC, Hebert AA. Therapeutic challenges in managing pediatric psoriasis. Int J Womens Dermatol. 2021;7(3):314–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Peris K, Fortina AB, Bianchi L, Fabbrocini G, Gisondi P, Balato A, et al. Update on the management of pediatric psoriasis: an Italian consensus. Dermatol Ther (Heidelb). 2022;12(8):1753–75. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Cosentyx [summary of product characteristics]. East Hanover, NJ. Novartis Pharmaceuticals Corporation; 2023.
  • 12.COSENTYX [package insert]. East Hanover, NJ. Novartis Pharmaceuticals Corporation; 2023.
  • 13.Narbutt J, Niedźwiedź M, Lesiak A, Ceryn J, Skibińska M. Secukinumab for the treatment of psoriasis in pediatrics: patient selection and acceptability. Patient Prefer Adherence. 2023;17:421–31. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Magnolo N, Kingo K, Laquer V, Browning J, Reich A, Szepietowski JC, et al. Efficacy of secukinumab across subgroups and overall safety in pediatric patients with moderate to severe plaque psoriasis: week 52 results from a phase III randomized study. Paediatr Drugs. 2022;24(4):377–87. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Magnolo N, Kingo K, Laquer V, Browning J, Reich A, Szepietowski JC, et al. A phase 3 open-label, randomized multicenter study to evaluate efficacy and safety of secukinumab in pediatric patients with moderate to severe plaque psoriasis: 24-week results. J Am Acad Dermatol. 2022;86(1):122–30. [DOI] [PubMed] [Google Scholar]
  • 16.Di Lernia V, Macca L, Peterle L, Ingrasciotta Y, Trifirò G, Guarneri C. Efficacy of systemic biologic drugs in pediatric psoriasis: evidence from five selected randomized clinical trials. Front Pharmacol. 2022;13: 847308. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Wang WM, Jin HZ. Biologics in pediatric psoriasis. J Dermatol. 2023;50(4):415–21. [DOI] [PubMed] [Google Scholar]
  • 18.Krasowska D, Gambichler T, Cortés C, Horev A, Compagno N, Dahale SS, et al. Long-term efficacy, safety and tolerability of secukinumab in children and adolescents with severe chronic plaque psoriasis: two-year results from a phase III double-blind, randomized controlled trial. J Eur Acad Dermatol Venereol. 2023. 10.1111/jdv.19063. [DOI] [PubMed] [Google Scholar]
  • 19.Langley RG, Sofen H, Dei-Cas I, Reich K, Sigurgeirsson B, Warren RB, et al. Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III ERASURE and FIXTURE trials. Br J Dermatol. 2022;188(2):198–207. [DOI] [PubMed] [Google Scholar]
  • 20.Bissonnette R, Luger T, Thaçi D, Toth D, Lacombe A, Xia S, et al. Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE extension study). J Eur Acad Dermatol Venereol. 2018;32(9):1507–14. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Foley P, Spelman L, Murrell DF, Mate E, Tronnberg R, Lowe PM. Secukinumab treatment showed improved quality of life in patients with chronic plaque psoriasis in Australia: results from the HOPE study. Australas J Dermatol. 2022;63(3):312–20. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Augustin M, Dauden E, Mrowietz U, Konstantinou MP, Gerdes S, Kingo K, et al. Secukinumab treatment leads to normalization of quality of life and disease symptoms in psoriasis patients with or without prior systemic psoriasis therapy: the PROSE study results. J Eur Acad Dermatol Venereol. 2021;35(2):431–40. [DOI] [PubMed] [Google Scholar]
  • 23.Gottlieb AB, Deodhar A, McInnes IB, Baraliakos X, Reich K, Schreiber S, et al. Long-term safety of secukinumab over five years in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis and ankylosing spondylitis: update on integrated pooled clinical trial and post-marketing surveillance data. Acta Derm Venereol. 2022;102: adv00698. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.EMA (2012) Ethical considerations for pediatric trials. https://www.ema.europa.eu/en/documents/report/ethical-considerations-paediatrictrials_en.pdf. Accessed 29 Oct 2020.

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Data Availability Statement

The datasets generated and/or analyzed during the current study are not publicly available. Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. These requests are reviewed and approved on the basis of scientific merit. All data provided are anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. The data may be requested from the corresponding author of the manuscript.


Articles from Paediatric Drugs are provided here courtesy of Springer

RESOURCES